Response Guided Therapy (RGT) for Boceprevir Combined With Peginterferon Alpha-2b Plus Ribavirin in Naive Hispanic Patients With Genotype 1 Hepatitis C Infection.

Trial Profile

Response Guided Therapy (RGT) for Boceprevir Combined With Peginterferon Alpha-2b Plus Ribavirin in Naive Hispanic Patients With Genotype 1 Hepatitis C Infection.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 03 Jul 2015

At a glance

  • Drugs Boceprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 09 Jul 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov record.
    • 09 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top